Regeneron Pharmaceuticals (NASDAQ:REGN) announced on Friday that the U.S. FDA approved a label expansion for its anti-cholesterol agent Evkeeza, marketed globally with Ultragenyx Pharmaceuticals (NASDAQ:RARE). Accordingly, the injectable, first approved in 2021 for adults and adolescents with homozygous familial hypercholesterolemia ((HoFH)), will also be ...